Caracterização clínica e imunoistoquímica dos adenomas clinicamente não-funcionantes de hipófise: clinical features and immunohistochemistry
暂无分享,去创建一个
F. Schmitt | L. Naves | V. Nosé | C. Botelho | P. Mello | C. A. Botelho | L. A. Naves | A. V. Magalhães | Jane Eyre Alves Ferreira | Vânia Nosé | Fernando Schmitt
[1] S. Chevillard,et al. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer , 2005, Breast Cancer Research and Treatment.
[2] J. Lawson,et al. Microcysts and Breast Cancer: A Study of Biological Markers in Archival Biopsy Material , 2002, Breast Cancer Research and Treatment.
[3] J. Rutka,et al. Genetic Basis of Pituitary Adenoma Invasiveness: A Review , 2001, Journal of Neuro-Oncology.
[4] I. Christensen,et al. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy , 2000, Breast Cancer Research and Treatment.
[5] D. Lüdecke,et al. Proliferation Markers in Different Types of Clinically Non-Secreting Pituitary Adenomas , 1999, Pituitary.
[6] L. Beckman,et al. Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. , 2004, European journal of cancer.
[7] B. Scheithauer,et al. Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases. , 2003, Journal of neurosurgery.
[8] D. Jablons,et al. Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2. , 2003, Archives of pathology & laboratory medicine.
[9] S. Tsutsui,et al. Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. , 2003, American journal of surgery.
[10] P. Karakitsos,et al. Image analysis (DNA ploidy) and expression of c-erb B-2 and p53 in imprint smears of breast cancer. , 2003, European journal of gynaecological oncology.
[11] C. Morrison,et al. C-erb B2 (Her2/ neu) Is Neither Overexpressed nor Amplified in Hepatic Neoplasms , 2002, Applied immunohistochemistry & molecular morphology : AIMM.
[12] N. Ferreira,et al. Expression of p53 protein in pituitary adenomas. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[13] S. Tsutsui,et al. Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer , 2002, Breast cancer.
[14] G. Maira,et al. Anterior pituitary adenomas in patients aged more than 65 years: analysis of growth fraction (using the MIB-1 monoclonal antibody) and of clinical features in comparison to younger patients , 2002, Clinical Neurology and Neurosurgery.
[15] Marcin Schmidt,et al. Immunohistochemical assay of p53, cyclin D1, c-erbB2, EGFr and Ki-67 proteins in HPV-positive and HPV-negative cervical cancers. , 2002, Folia histochemica et cytobiologica.
[16] K I Bland,et al. Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53 , 2001, Annals of surgery.
[17] J. Royds,et al. Mdm2 and the p53 pathway in human pituitary adenomas , 2001, Clinical endocrinology.
[18] A. Lewiński,et al. Correlation between PCNA expression and AgNOR dots in pituitary adenomas , 2001, Endocrine pathology.
[19] R. Delcelo,et al. [Pituitary adenomas: relationship between invasiveness and proliferative cell nuclear index]. , 2000, Arquivos de neuro-psiquiatria.
[20] T. Kokunai,et al. Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression , 1999, Journal of Clinical Neuroscience.
[21] L. Blevins,et al. Aggressive pituitary tumors. , 1998, Oncology.
[22] R. Seruca,et al. P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach. , 1998, Pathology, research and practice.
[23] S. Atkin,et al. A comparison of proliferation indices in human anterior pituitary adenomas using formalin-fixed tissue and in vitro cell culture. , 1997, Journal of neurosurgery.
[24] C. Christov,et al. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index. , 1997, General & diagnostic pathology.
[25] S. Melmed,et al. Genetic basis of endocrine disease: pituitary tumor pathogenesis. , 1997, The Journal of clinical endocrinology and metabolism.
[26] K. Takakura,et al. [The relationship between cell proliferation activity and secretory activity in pituitary adenoma--a review of 63 cases]. , 1996, No to shinkei = Brain and nerve.
[27] J. Xiao,et al. Molecular and cellular responses to DNA damage in a murine pituitary adenoma cell line , 1996, Molecular and Cellular Endocrinology.
[28] Y. Yonemasu,et al. Dural invasion and proliferative potential of pituitary adenomas. , 1996, Neurologia medico-chirurgica.
[29] S. Lightman,et al. p53 gene mutations in pituitary adenomas: rare events , 1994, Clinical endocrinology.
[30] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[31] A. Klibanski,et al. Clinical review 45: Clinically nonfunctioning pituitary adenomas. , 1993, The Journal of clinical endocrinology and metabolism.
[32] S. Syrjänen,et al. Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance. , 1991, Anticancer research.
[33] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.